about
Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer CellsDiffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis.Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapyA targeted mutational landscape of angioimmunoblastic T-cell lymphoma.Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma.RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer.Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1Progress against follicular lymphomaA rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literatureEvidence Suggesting That Discontinuous Dosing of ALK Kinase Inhibitors May Prolong Control of ALK+ Tumors.TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis.Kinase overexpressing cancers responsive to drug withdrawal.Sirolimus (rapamycin) induced proteinuria in a patient undergoing allogeneic hematopoietic stem cell transplant.ATP-competitive, marine derived natural products that target the DEAD box helicase, eIF4A.Double hit lymphoma presenting as haemophagocytic lymphohistiocytosis.Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas.A Phase II Exploratory Study of PXD-101 (Belinostat) Followed by Zevalin in Patients with Relapsed Aggressive High-Risk Lymphoma.Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy after Cytoreduction with ESHAP Chemotherapy in Patients with Relapsed Follicular Non-Hodgkin Lymphoma: Final Results of a Phase II Study.Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with Antitumor ActivityComplications of Intrathecal Chemotherapy in Adults: Single-Institution Experience in 109 Consecutive Patients.eIF4A inhibition: ready for primetime?Statins enhance efficacy of venetoclax in blood cancers.Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiationTargeting the PI3K/AKT/mTOR pathway in non-Hodgkin's lymphoma: results, biology, and development strategiesThe mechanism of cancer drug addiction in ALK-positive T-Cell lymphomaShort survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentationCentral Nervous System Involvement by Small Lymphocytic Lymphoma after a Myxoma-Related Embolic EventT Cell-Activating Bispecific Antibodies in Cancer TherapyCRISPR genome editing of murine hematopoietic stem cells to create Npm1-Alk causes ALK+ lymphoma after transplantationA network of RNA-binding proteins controls translation efficiency to activate anaerobic metabolism
P50
Q26774625-66B16C09-90D5-43C8-998A-72545A1964ABQ33622342-8E6D192A-38D4-428D-9FCC-D41EB2561294Q34282231-A9B70979-5A95-4605-AF0B-B23EE6FFAD82Q34423830-BB174AC7-5AAF-4C77-A1E1-8EA4307DA9FFQ34663596-E3C649F9-9C19-4166-B1BB-07DC90A40222Q35208375-BCEEFD7D-FEBC-4B67-951A-A354DF26DCD4Q35216351-62D4618F-F4CF-451D-B180-7D95147E9008Q35920657-9133EFB7-0CDD-47DD-9EAD-C5BF0F5485C2Q38106809-43630AD5-4805-4482-B6E3-F8F970BEAB6BQ38283586-1C8639B6-60A5-4B04-B55B-A40D429AB908Q38870250-4FC493C7-2FF7-4727-9EEF-663ECD16EE2EQ41133791-03657070-F3F5-4503-B729-56B4042469F2Q42319925-F72248D2-0D1B-46D4-AAA9-8C389582F716Q43094875-6C37D58D-DAF3-4574-813B-1D61300B9862Q43184268-F12E0044-4218-4E77-A0F8-CEAA8FEF10D5Q46486874-7FE34829-39A4-4C60-B404-589C26BDC3DCQ48011779-9E7042C6-74D9-4FA6-AF31-3FA41712E054Q48135143-D06FCB73-D33A-4923-BCA2-202457675A96Q50065599-908F1632-46E6-43D9-9786-D9FA26ECD129Q50224892-99F37A9E-C024-489A-BAC5-12B224CC3D49Q52689720-2A9C1E29-CBD2-4497-82E2-D65BB61F013CQ57753144-14996A8C-14CD-4365-8825-AFCDD2D1F2ACQ64935160-056F183D-1895-45B4-B923-741D87CC3B31Q64950299-0810C0F4-1E6C-44B2-8203-95C62723B09FQ64963526-7333EE63-5E1F-4DAD-A33C-6F54A68A380AQ80139485-31EF31C1-52ED-4569-A7C6-31C8B660AFE6Q84556627-6351FDB7-EE6B-45D3-A392-F3D5956EE283Q91718675-4F50281A-8029-4673-802A-081BB843A463Q91734657-D6D3A72E-1A83-439E-A2E3-F14D0C29DB7BQ91898934-B52313FF-FD95-4FBD-8460-895525AEA514Q92091431-06AB4E25-C0FE-4543-A362-7E3E2DD05D0EQ92688560-54D787E8-7C50-4B77-A14A-DAF7E9F6E893Q96022843-3A3603F7-0B9B-4381-A2E3-13265983B4E3
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jonathan H Schatz
@ast
Jonathan H Schatz
@en
Jonathan H Schatz
@es
Jonathan H Schatz
@nl
type
label
Jonathan H Schatz
@ast
Jonathan H Schatz
@en
Jonathan H Schatz
@es
Jonathan H Schatz
@nl
prefLabel
Jonathan H Schatz
@ast
Jonathan H Schatz
@en
Jonathan H Schatz
@es
Jonathan H Schatz
@nl
P106
P21
P31
P496
0000-0003-1842-228X